Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma Presented ByDr Yohann Loriot, Institut Gustave Roussy, France TrialPhase 3, LEAP-011 ConferenceASCO GU 2022 TypePeer-reviewed article 8 April 2022 11:18